Company news
Lexicon Pharmaceuticals, Inc. news in 2022
Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
December 20, 2022
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
November 13, 2022
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
November 8, 2022
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
October 23, 2022
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
August 4, 2022
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 1, 2022
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
July 28, 2022
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
July 27, 2022
Lexicon Announces Proposed Public Offering Of Common Stock
July 26, 2022
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
July 26, 2022
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
June 28, 2022
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
May 30, 2022
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
May 4, 2022
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
February 27, 2022
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
February 27, 2022
Calls in 2022
- Lexicon Pharmaceuticals (NASDAQ:LXRX) Q3 2022 Earnings Call
Nov 9, 2022
Transcript - Lexicon Pharmaceuticals (NASDAQ:LXRX) Q2 2022 Earnings Call
Aug 2, 2022
Transcript - Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2022 Earnings Call
May 5, 2022
Transcript - Lexicon Pharmaceuticals (NASDAQ:LXRX) Q4 2021 Earnings Call
Feb 28, 2022
Transcript